MEDPACE HOLDINGS INC•Financial Summary•AI-Powered Insights

MEDPACE HOLDINGS INC 2026 Q3
Earnings Overview & AI Insights

Detailed performance report for MEDPACE HOLDINGS INC covering Q3 2026. Gain clarity on earnings, revenue trends, and AI-enhanced strategic analysis.

MEDPACE HOLDINGS INC (2026 Q3)

Earnings Performance

No Performance Data

Summary of Financial Performance: Medpace reported Q3 2026 revenue of $716 million, up 8.5% year over year, with 9M revenue of $2.13 billion, up 16.9%. EBITDA rose 16% to $172.1 million in Q3, with margin expanding to 24.0% from 22.5% due mainly to lower reimbursable costs. Net income increased 23.7% to $137.5 million, and diluted EPS was $4.84 versus $3.86 last year. Backlog was approximately $3.2 billion, up 5.6%, with $1.99 billion expected to convert to revenue in the next 12 months. Cash flow from operations was $217 million, and cash ended at $705.3 million.

Company Outlook & Strategy: Management raised full-year 2026 guidance, now expecting revenue of $2.835 billion to $2.855 billion, EBITDA of $638 million to $652 million, net income of $514 million to $524 million, and EPS of $17.97 to $18.32. Management said there is no large disconnect between current analyst consensus and its 2027 modeling, but formal 2027 guidance will be provided with Q4 results in February. The board also approved a new $1 billion share repurchase authorization. The company emphasized continued execution, strong win rates, and favorable demand momentum.

Key Industry Trends: Management described the business environment as strong, with high-quality RFP activity and strong initial award notifications. The mix of demand appears to be shifting somewhat, with more traditional oncology activity and less metabolic demand at the current time. Competitive conditions remain active, but Medpace believes its differentiation and win rate are holding up well in a healthy market.

Operational Highlights: Net new business awards entering backlog increased 10.6% year over year to $873 million in Q3, and last-12-month net new awards reached $3.02 billion, up 23.9%. Backlog conversion in Q3 was 23.8% of beginning backlog. Management noted that cancellations were toward the higher end of the expected range, but not an unusual callout. The company also highlighted strong cash generation and a negative net days sales outstanding position of -66 days.

Challenges & Risks: Management flagged backlog cancellations as somewhat elevated, though still within expected range. Customer concentration remains notable, with the top 5 customers representing 31% of last-12-month revenue and the top 10 representing 39%. Guidance is also subject to foreign exchange rates and assumptions around tax rate, interest income, and share count. As always, execution risk remains tied to sustaining win rates and conversion of backlog into revenue.

Key Analyst Questions & Responses: Analysts focused on the strength of bookings, the competitive environment in biotech, pricing/differentiation, and how to interpret the company’s comment that consensus is in the right range. Management said the strong bookings reflect both a healthy market and Medpace’s solid win rate, with demand mix shifting somewhat toward oncology and away from metabolic studies. On consensus, management indicated current analyst estimates appear broadly consistent with its internal view, but declined to break out direct fee revenue versus pass-through revenue.

Earnings Call Transcript

Access the official earnings call transcript for MEDPACE-HOLDINGS-INC 2026 Q3. It provides valuable insights into management commentary, performance drivers, and forward-looking guidance directly from the company.